STAT3 and non-small cell lung carcinoma: Sun et al. (36) found that miR-202 canincrease therapeutic effect of cisplatin against NSCLCvia inhibiting activity of the Ras/MAPK pathway.Zhao et al. (37) revealed that up-regulation of miR-202significantly reduces NSCLC cell viability, migrationand invasion, and they suggested that STAT3 shouldbe a direct target of miR-202.